Long-Term Clinical Outcome of First Recurrence Skull Base Meningiomas.
adjuvant radiotherapy
anaplastic
atypical
recurrence
skull base meningioma
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 Dec 2019
31 Dec 2019
Historique:
received:
19
11
2019
revised:
10
12
2019
accepted:
29
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
8
1
2020
Statut:
epublish
Résumé
Skull base meningiomas (SBMs) are considered to be less aggressive and have a slower growth rate than non-SBMs. However, SBMs often develop local recurrences after surgical resection. Gross total removal is difficult because SBMs are deep-seated tumors and involve critical neurovascular structures. The treatment strategy for recurrent SBMs remains controversial. The present study aimed to evaluate the long-term clinical course and prognostic factors associated with shorter progression-free survival (PFS) of recurrent SBMs. This retrospective study included 85 recurrent SBMs from 65 patients who underwent surgery from January 2005 to September 2018. Overall survival (OS) and PFS were evaluated, and the associations among shorter PFS and age, sex, tumor size, lesions, World Health Organization (WHO) grading, removal rate, and time since prior surgery were analyzed. The median follow-up period for PFS was 68 months. The 2-, 5-, and 10-year PFS rates were 68.0%, 52.8%, and 22.7%, respectively. WHO grade II or III, multiple lesions, and tumor size were significantly associated with shorter PFS (
Identifiants
pubmed: 31906133
pii: jcm9010106
doi: 10.3390/jcm9010106
pmc: PMC7019997
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Neurooncol. 2018 May;138(1):63-71
pubmed: 29353434
Neuro Oncol. 2019 Feb 14;21(2):234-241
pubmed: 30085283
J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39
pubmed: 13406590
Acta Neurochir (Wien). 2013 Mar;155(3):407-13
pubmed: 23318687
J Neurosurg. 2018 Mar 16;130(2):360-367
pubmed: 29547085
J Neurooncol. 2019 Aug;144(1):65-77
pubmed: 31240525
Neurosurgery. 2019 Nov 1;85(5):E910-E916
pubmed: 31329941
Neurosurg Rev. 2019 Dec;42(4):961-972
pubmed: 29978438
Cancer Med. 2019 Jan;8(1):13-20
pubmed: 30680963
J Neurosurg. 2018 May 4;130(3):876-883
pubmed: 29726777
Neurosurg Rev. 2019 Mar;42(1):163-173
pubmed: 29627874
J Korean Neurosurg Soc. 2015 Apr;57(4):258-65
pubmed: 25932292
World Neurosurg. 2019 May;125:e790-e796
pubmed: 30738945
Sci Rep. 2019 Apr 11;9(1):5944
pubmed: 30976047
J Neurooncol. 2017 Jul;133(3):641-651
pubmed: 28527009
Neuro Oncol. 2017 Sep 1;19(9):1263-1270
pubmed: 28371851
J Neurosurg. 2018 May;128(5):1403-1409
pubmed: 28731398
World Neurosurg. 2018 Apr;112:e74-e83
pubmed: 29258946
J Neurooncol. 2014 Jan;116(2):381-6
pubmed: 24257965
J Neurosurg. 2012 Mar;116(3):574-80
pubmed: 22175721
World Neurosurg. 2017 Jun;102:139-143
pubmed: 28300708
World Neurosurg. 2019 Jul;127:e221-e229
pubmed: 30880202
J Neurosurg. 2010 May;112(5):925-33
pubmed: 19799498
J Neurooncol. 2016 Sep;129(2):281-8
pubmed: 27311730
Clin Neurol Neurosurg. 2016 Feb;141:117-21
pubmed: 26780494
Neuro Oncol. 2015 Jan;17(1):116-21
pubmed: 25100872
J Neurosurg. 2016 Aug;125(2):431-40
pubmed: 26722844
J Neurosurg. 2017 Jun;126(6):1822-1828
pubmed: 27611201
J Neurosurg. 2017 Jan;126(1):201-211
pubmed: 27058201
J Cancer Res Clin Oncol. 2019 May;145(5):1351-1360
pubmed: 30953136
J Oncol Pharm Pract. 2019 Apr;25(3):638-647
pubmed: 30253729
Clin Neurol Neurosurg. 2015 Jan;128:112-6
pubmed: 25486076
Neuroradiology. 2019 Dec;61(12):1355-1364
pubmed: 31324948
Cancer. 2011 Mar 15;117(6):1272-8
pubmed: 21381014